

Publikationen 2005

Originalarbeiten

Aceto L, Karrer U, Grube C, Oberholzer R, Hasse B, Presterl E, Boni J, Kuster H, Trkola A, Weber R, Gunthard HF. Primary HIV-1 infection in Zurich: 2002-2004. *Schweiz Rundsch Med Prax* 2005;94(32):1199-205.

Audige A, Schlaepfer E, Joller H, Speck RF. Uncoupled anti-HIV and immune-enhancing effects when combining IFN-alpha and IL-7. *J Immunol* 2005;175(6):3724-36.

Balajee SA, Imhof A, Gribskov JL, Marr KA. Determination of antifungal drug susceptibilities of *Aspergillus* species by a fluorescence-based microplate assay. *J Antimicrob Chemother* 2005;55(1):102-5.

Banki Z, Kacani L, Rusert P, Pruenster M, Wilflingseder D, Falkensammer B, Stellbrink HJ, van Lunzen J, Trkola A, Dierich MP, Stoiber H. Complement dependent trapping of infectious HIV in human lymphoid tissues. *Aids* 2005;19(5):481-6.

Bruggmann P, Seidenberg A, Meili D, Kesseli B, Huber M. Hepatitis C- und HIV-Prävalenz sowie antiretrovirale Therapie in einem niedrigrschwelligem Substitutionsprogramm – eine Querschnittsanalyse. *Suchttherapie* 2005;6:78-82.

Cilliers T, Willey S, Sullivan WM, Patience T, Pugach P, Coetzer M, Papathanasopoulos M, Moore JP, Trkola A, Clapham P, Morris L. Use of alternate coreceptors on primary cells by two HIV-1 isolates. *Virology* 2005;339(1):136-44.

Cozzi-Lepri A, Ruiz L, Loveday C, Phillips AN, Clotet B, Reiss P, Ledergerber B, Holkmann C, Staszewski S, Lundgren JD. Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. *Antivir Ther* 2005;10(7):791-802.

d'Arminio Monforte A, Sabin CA, Phillips A, Sterne J, May M, Justice A, Dabis F, Grabar S, Ledergerber B, Gill J, Reiss P, Egger M. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. *Arch Intern Med* 2005;165(4):416-23.

Eggimann P, Calandra T, Fluckiger U, Bille J, Garbino J, Glauser MP, Marchetti O, Ruff C, Tauber M, Pittet D. Invasive candidiasis: comparison of management choices by infectious disease and critical care specialists. *Intensive Care Med* 2005;31(11):1514-21.

Fagard C, Bandelier CY, Ananworanich J, Le Braz M, Gunthard H, Perneger T, Garcia F, Hirschel B. Biphasic decline of CD4 cell count during scheduled treatment interruptions. *Aids* 2005;19(4):439-41.

Fleisch F, Oechslin EC, Gujer AR, Ritzler E, Imhof A, Ruff C, Reinhart WH. Transregional spread of a single clone of methicillin-resistant *Staphylococcus aureus* between groups of drug users in Switzerland. *Infection* 2005;33(4):273-7.

Gamperli A, Bosshard PP, Sigrist T, Brandli O, Wildermuth S, Weber R, Mueller NJ. Pulmonary Mycobacterium sherrisii infection in a human immunodeficiency virus type 1- infected patient. *J Clin Microbiol* 2005;43(8):4283-5.

Gruner C, Zinkernagel AS, Mueller NJ, Himmelmann A, Gunthard HF, Seebach JD. Hypersensitivitätssyndrom unter antibiotischer Dreierkombination. *Schweizerisches Medizinisches Forum* 2005;5:698-700.

Hasse B, Gunthard HF, Bleiber G, Krause M. Efavirenz intoxication due to slow hepatic metabolism. *Clin Infect Dis* 2005;40(3):e22-3.

Hasse B, Strebel B, Thurnheer R, Uhlmann F, Krause M. Chronic necrotizing pulmonary aspergillosis after tuberculosis in an HIV-positive woman: an unusual immune reconstitution phenomenon? *Aids* 2005;19(18):2179-81.

Huber M, Weber R, Oppliger R, Vernazza P, Schmid P, Schonbucher P, Bertisch B, Meili D, Renner EL. Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial. *Infection* 2005;33(1):25-9.

Hurlimann D, Chenevard R, Ruschitzka F, Flepp M, Enseleit F, Bechir M, Kobza R, Muntwyler J, Ledergerber B, Luscher TF, Noll G, Weber R. Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing antiretroviral combination therapy: a randomised double blind crossover trial. *Heart* 2006;92(1):110-2.

Imhof A, Ledergerber B, Gunthard HF, Haupts S, Weber R. Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring? *Clin Infect Dis* 2005;41(5):721-8.

Joos B, Trkola A, Fischer M, Kuster H, Rusert P, Leemann C, Boni J, Oxenius A, Price DA, Phillips RE, Wong JK, Hirschel B, Weber R, Gunthard HF. Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions. *J Virol* 2005;79(14):9026-37.

Karrer U, Ledergerber B, Furrer H, Elzi L, Battegay M, Cavassini M, Gayet-Ageron A, Hirschel B, Schmid P, Russotti M, Weber R, Speck RF. Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. *Aids* 2005;19(17):1987-94.

Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. *Clin Infect Dis* 2005;41(3):361-72.

Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K, Vella S, Kirk O, Lundgren JD. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. *Aids* 2005;19(6):593-601.

Kronenberg A, Bossart W, Wuthrich RP, Cao C, Lautenschlager S, Wiegand ND, Mullhaupt B, Noll G, Mueller NJ, Speck RF. Retrospective analysis of varicella zoster virus (VZV) copy DNA numbers in plasma of immunocompetent patients with herpes zoster, of immunocompromised patients with disseminated VZV disease, and of asymptomatic solid organ transplant recipients. *Transpl Infect Dis* 2005;7(3-4):116-21.

Kuwaki K, Tseng YL, Dor FJ, Shimizu A, Houser SL, Sanderson TM, Lancos CJ, Prabharasuth DD, Cheng J, Moran K, Hisashi Y, Mueller N, Yamada K, Greenstein JL, Hawley RJ, Patience C, Awwad M, Fishman JA, Robson SC, Schuurman HJ, Sachs DH, Cooper DK. Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. *Nat Med* 2005;11(1):29-31.

Lowy A, Page J, Jaccard R, Ledergerber B, Somaini B, Weber R, Szucs T. Costs of treatment of Swiss patients with HIV on antiretroviral therapy in hospital-based and general practice-based care: a prospective cohort study. *AIDS Care* 2005;17(6):698-710.

Mocroft A, Rockstroh J, Soriano V, Ledergerber B, Kirk O, Vinogradova E, Reiss P, Katlama C, Phillips AN, Lundgren JD. Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection? *Antivir Ther* 2005;10(7):779-90.

Mueller NJ, Kuwaki K, Knosalla C, Dor FJ, Gollackner B, Wilkinson RA, Arn S, Sachs DH, Cooper DK, Fishman JA. Early weaning of piglets fails to exclude porcine lymphotropic herpesvirus. *Xenotransplantation* 2005;12(1):59-62.

Olsen CH, Gatell J, Ledergerber B, Katlama C, Friis-Moller N, Weber J, Horban A, Staszewski S, Lundgren JD, Phillips AN. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen. *Aids* 2005;19(3):319-30.

Qi W, Ender M, O'Brien F, Imhof A, Ruef C, McCallum N, Berger-Bachi B. Molecular epidemiology of methicillin-resistant *Staphylococcus aureus* in Zurich, Switzerland (2003): prevalence of type IV SCCmec and a new SCCmec element associated with isolates from intravenous drug users. *J Clin Microbiol* 2005;43(10):5164-70.

Rauch A, Rickenbach M, Weber R, Hirschel B, Tarr PE, Bucher HC, Vernazza P, Bernasconi E, Zinkernagel AS, Evison J, Furrer H. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. *Clin Infect Dis* 2005;41(3):395-402.

Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, Kirk O, Phillips AN, Ledergerber B, Lundgren J. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. *J Infect Dis* 2005;192(6):992-1002.

Rotger M, Taffe P, Bleiber G, Gunthard HF, Furrer H, Vernazza P, Drechsler H, Bernasconi E, Rickenbach M, Telenti A. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. *J Infect Dis* 2005;192(8):1381-6.

Rusert P, Kuster H, Joos B, Misselwitz B, Gujer C, Leemann C, Fischer M, Stiegler G, Katinger H, Olson WC, Weber R, Aceto L, Gunthard HF, Trkola A. Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. *J Virol* 2005;79(13):8454-69.

Schaer DJ, Schleiffenbaum B, Kurrer M, Imhof A, Bachli E, Fehr J, Moller HJ, Moestrup SK, Schaffner A. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineagespecific marker in the reactive hemophagocytic syndrome. *Eur J Haematol* 2005;74(1):6-10.

Schraner C, Hasse B, Hasse U, Baumann D, Faeh A, Burg G, Grimm F, Mathis A, Weber R, Gunthard HF. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1. *Clin Infect Dis* 2005;40(12):e120-4.

Schupbach J, Gunthard H, Joos B, Fischer M, Boni J, Tomasik Z, Yerly S, Perrin L, Battegay M, Furrer H, Vernazza P, Bernasconi E, Hirschel B. HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. *J Acquir Immune Defic Syndr* 2005;40(3):250-6.

Stemmler J, Markwalder KA, Zinkernagel AS, Wirth MG, Grimm F, Hirsch-Hoffmann S, Thiel MA. Loa loa infection of the eye -- a case series. *Klin Monatsbl Augenheilkd* 2005;222(3):226-30.

Sterne JA, Hernan MA, Ledergerber B, Tilling K, Weber R, Sendi P, Rickenbach M, Robins JM, Egger M. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. *Lancet* 2005;366(9483):378-84.

Strain MC, Little SJ, Daar ES, Havlir DV, Gunthard HF, Lam RY, Daly OA, Nguyen J, Ignacio CC, Spina CA, Richman DD, Wong JK. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. *J Infect Dis* 2005;191(9):1410-8.

Strain MC, Letendre S, Pillai SK, Russell T, Ignacio CC, Gunthard HF, Good B, Smith DM, Wolinsky SM, Furtado M, Marquie-Beck J, Durelle J, Grant I, Richman DD, Marcotte T, McCutchan JA, Ellis RJ, Wong JK. Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. *J Virol* 2005;79(3):1772-88.

Talbot TR, Bradley SE, Cosgrove SE, Ruef C, Siegel JD, Weber DJ. Influenza vaccination of healthcare workers and vaccine allocation for healthcare workers during vaccine shortages. *Infect Control Hosp Epidemiol* 2005;26(11):882-90.

Tarr PE, Taffe P, Bleiber G, Furrer H, Rotger M, Martinez R, Hirschel B, Battegay M, Weber R, Vernazza P, Bernasconi E, Darioli R, Rickenbach M, Ledergerber B, Telenti A. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. *J Infect Dis* 2005;191(9):1419-26.

Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, Manrique A, Huber M, Rehr M, Oxenius A, Weber R, Stiegler G, Vcelar B, Katinger H, Aceto L, Gunthard

HF. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. *Nat Med* 2005;11(6):615-22.

Vora S, Marcelin AG, Gunthard HF, Flandre P, Hirsch HH, Masquelier B, Zinkernagel A, Peytavin G, Calvez V, Perrin L, Yerly S. Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. *Aids* 2006;20(1):35-40.

Wunder D, Bersinger NA, Fux C, Weber R, Bernasconi E, Cavassini M, Bucher HC, Schiffer V, Schmid P, Furrer H. Plasma leptin levels in men are not related to the development of lipoatrophy during antiretroviral therapy. *Aids* 2005;19(16):1837-42.

Yazdanpanah Y, De Carli G, Miguères B, Lot F, Campins M, Colombo C, Thomas T, Deuffic-Burban S, Prevot MH, Domart M, Tarantola A, Abiteboul D, Deny P, Pol S, Desenclos JC, Puro V, Bouvet E. Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. *Clin Infect Dis* 2005;41(10):1423-30.

Young J, Rickenbach M, Weber R, Furrer H, Bernasconi E, Hirschel B, Tarr PE, Vernazza P, Battegay M, Bucher HC. Body fat changes among antiretroviral-naïve patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study. *Antivir Ther* 2005;10(1):73-81.

Young J, Weber R, Rickenbach M, Furrer H, Bernasconi E, Hirschel B, Tarr PE, Vernazza P, Battegay M, Bucher HC. Lipid profiles for antiretroviral-naïve patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. *Antivir Ther* 2005;10(5):585-91.

Zingg W, Colombo C, Jucker T, Bossart W, Ruef C. Impact of an outbreak of norovirus infection on hospital resources. *Infect Control Hosp Epidemiol* 2005;26(3):263-7.

Zinkernagel AS, Speck RF, Ruef C, Zingg W, Berger-Bachi B, Springer B. Rapidly destructive *Staphylococcus epidermidis* endocarditis. *Infection* 2005;33(3):148-50.

Zinkernagel AS, von Overbeck J, Opravil M, Jenni R, Speich R, Mueller NJ. Long-term survival and interruption of HAART in HIV-related pulmonary hypertension. *Eur J Clin Microbiol Infect Dis* 2005;24(2):153-5.

Originalpublikationen in print (2006)

Bertschy S, Opravil M, Telenti A, Bernasconi E, Schiffer V, Vernazza P, Flepp M, Chave JP, Christen A, Furrer H. Discontinuation of maintenance therapy against *Toxoplasma* encephalitis among HIV-infected patients with sustained response to antiretroviral therapy. *Clinical Microbiology and Infection* 2006;in print.

Glass TR, De Geest S, Weber R, Vernazza P, Rickenbach M, Furrer H, Bernasconi E, Cavassini M, Hirschel B, Battegay M, Bucher HC. Correlates of self reported non-adherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. *J Acquir Immune Deficiency* 2006;in print.

Joos B, Trkola A, Aceto L, Fischer M, Vcelar B, Stiegler G, Katinger H, Kuster H, Gunthard H. Multiple dose pharmacokinetics of combined anti-HIV-1 human

monoclonal antibodies 2G12, 4E10 and 2F5 administered intravenously to HIV-infected patients. *Antimicrobial Agents and Chemotherapy* 2006.

Knuchel MC, Tomasik Z, Speck RF, Luthy R, Schupbach J. Ultrasensitive quantitative HIV-1 p24 antigen assay adapted to dried plasma spots to improve treatment monitoring in lowresource settings. *J Clin Virol* 2006.

Law MG, Friis-Moller N, El-Sadr WM, Weber R, Reiss P, d'Arminio Monforte A, Thiébaud R, Morfeldt L, de Wit S, Pradier C, Calvo G, Kirk O, Sabin CA, Phillips A, Lundgren J. The Use of the Framingham Equation to Predict Myocardial Infarctions in HIV-infected Patients: Comparison with Observed Events in the D:A:D Study. *HIV Med* 2006;in print.

Mueller V, Ledergerber B, Perrin L, Klimkait T, Furrer H, Telenti A, Bernasconi E, Vernazza P, Gunthard HF, Bonhoeffer S. Stable virulence levels in the HIV epidemic of Switzerland over two decades. *Aids* 2006;in print.

Panackal AA, Imhof A, Hanley EW, Marr KA. Outbreaks of *Aspergillus ustus* infection among transplant recipients. *Emerging Infect Dis* 2006;in print.

Peyssonnaud C, Zinkernagel AS, Datta V, Lauth X, Johnson RS, Nizet V. TLR-4 dependent hepcidin expression by myeloid cells in response to bacterial pathogens. *Blood* 2006; in print.

Schlaepfer E, Audige A, Joller H, Speck RF. Toll-like receptor 7/8 triggering exerts opposing effects in acute versus latent HIV infection. *J Immunol* 2006;in print.

Simcock M, Sendi P, Ledergerber B, Keller T, Schüpbach J, Battegay M, Gunthard HF. A longitudinal analysis of health care costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off? *Antiviral Therapy* 2006;in print.

Zinkernagel A, von Wyl V, Ledergerber B, Rickenbach M, Furrer H, Battegay M, Hirschel B, Tarr PE, Opravil M, Bernasconi E, Schmid P, Weber R. Eligibility for and outcome of hepatitis C treatment of HIV co-infected persons in clinical practice: The Swiss HIV Cohort Study. *Antiviral Therapy* 2006;in print.

Kollaborationen

Bleiber G, May M, Martinez R, Meylan P, Ott J, Beckmann JS, Telenti A. Use of a combined ex vivo/in vivo population approach for screening of human genes involved in the human immunodeficiency virus type 1 life cycle for variants influencing disease progression. *J Virol* 2005;79(20):12674-80.

Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. *J Natl Cancer Inst* 2005;97(6):425-32.

Colombo S, Soranzo N, Rotger M, Sprenger R, Bleiber G, Furrer H, Buclin T, Goldstein D, Decosterd L, Telenti A. Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. *Pharmacogenet Genomics* 2005;15(9):599-608.

Fehr JS, Nicca D, Sendi P, Wolf E, Wagels T, Kiss A, Bregenzer T, Vernazza P, Jager H, Spirig R, Battegay M. Starting or changing therapy - a prospective study exploring antiretroviral decision-making. *Infection* 2005;33(4):249-56.

Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, Launay-Vacher V, Cheng A, Deray G. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1- infected patients. Data from a double-blind randomized active-controlled multicentre study. *Nephrol Dial Transplant* 2005;20(4):743-6.

Kinloch-de Loes S, Hoen B, Smith DE, Autran B, Lampe FC, Phillips AN, Goh LE, Andersson J, Tsoukas C, Sonnerborg A, Tambussi G, Girard PM, Bloch M, Battegay M, Carter N, El Habib R, Theofan G, Cooper DA, Perrin L. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. *J Infect Dis* 2005;192(4):607-17.

Manfredi R, Calza L, Chiodo F. An extremely different dysmetabolic profile between the two available nonnucleoside reverse transcriptase inhibitors: efavirenz and nevirapine. *J Acquir Immune Defic Syndr* 2005;38(2):236-8.

Rodriguez-Torres M, Torriani FJ, Soriano V, Borucki MJ, Lissen E, Sulkowski M, Dieterich D, Wang K, Gries JM, Hoggard PG, Back D. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study. *Antimicrob Agents Chemother* 2005;49(10):3997-4008.

Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, Keiser O, Biollaz J, Decosterd L, Telenti A. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. *Pharmacogenet Genomics* 2005;15(1):1-5.

Uebersichtsartikel / Reviews

Colombo C, Conrad C. Was können wir gegen Nadelstichverletzungen tun? *Krankenhaushygiene und Infektionsverhütung* 2005;2005(5):205-208.

Evison J, Aebi C, Francioli P, Péter O, Bassetti S, Gervaix A, Zimmerli S, Weber R. Abklärung und Therapie der Lyme-Borreliose bei Erwachsenen und Kindern: Empfehlungen der Schweizerischen Gesellschaft für Infektiologie. Teil 1: Epidemiologie und Diagnostik. *Schweizerische Ärztezeitung* 2005;86:2332-2338.

Evison J, Aebi C, Francioli P, Péter O, Bassetti S, Gervaix A, Zimmerli S, Weber R. Abklärung und Therapie der Lyme-Borreliose bei Erwachsenen und Kindern: Empfehlungen der Schweizerischen Gesellschaft für Infektiologie. Teil 2: Klinik und Therapie. *Schweizerische Ärztezeitung* 2005;86:2375-2384.

Evison J, Aebi C, Francioli P, Péter O, Bassetti S, Gervaix A, Zimmerli S, Weber R. Abklärung und Therapie der Lyme-Borreliose bei Erwachsenen und Kindern: Empfehlungen der Schweizerischen Gesellschaft für Infektiologie. Teil 3 Prävention, Schwangerschaft, Immundefizienz, Post-Lyme-Syndrom. *Schweizerische Ärztezeitung* 2005;86:2422-2428.

Hasse B, Moll C, Oehy K, Rothlin M, Krause M. Anti-infectious prophylaxis after splenectomy: current practice in an eastern region of Switzerland. *Swiss Med Wkly* 2005;135(19-20):291-6.

Hurlimann D, Weber R, Enseleit F, Luscher TF. HIV Infektion, antiretrovirale Therapie und Endothel. *Herz* 2005;30(6):472-80.

Imhof A, Schneemann M, Schaffner A. Therapie von invasiven Pilzinfektionen. *Swiss Medical Forum* 2005;5:136-144.

Mathis A, Weber R, Deplazes P. Zoonotic potential of the microsporidia. *Clin Microbiol Rev* 2005;18(3):423-45.

Ruef C. Clinical relevance of antibiotic resistance in obstetrics and gynecology. *Gynakol Geburtshilfliche Rundsch* 2005;45(1):19-27.

Speck RF, Brander C, Kundig TM. HIV-1 Impfungen - gibt es Hoffnung? *Ther Umsch* 2005;62(10):695-702.

Uebersichtsartikel / Reviews in print (2006)

Gamperli A, Hauser T, Speck RF. Risiko von Infektionen unter einer Behandlung mit Tumor Nekrose Faktor alpha-Inhibitoren. *Der Rheumatologe* 2006;in print.

Huttner B, Opravil M. Die infektiöse Spondylitis. *Zeitschrift für Rheumatologie* 2006;in print.

Mueller NJ, Fishman JA. Infectious risk in xenotransplantation. *Current Opinion in Organ Transplantation* 2006;in print.

Sudano I, Spieker LE, Noll G, Corti R, Weber R, Lüscher TF. Cardiovascular Disease in HIVinfection. *Am Heart J* 2006;in print.

Editorials

Ruef C. Nosocomial infections in intensive care units. *Infection* 2005;33(3):105.

Ruef C. Treatment of hepatitis C virus infection--is there progress? *Infection* 2005;33(1):1.

Weber R. Grippe bei Menschen und Hühnern im globalen Dorf: Zwischen Selbstgefälligkeit und Hysterie. *Schweiz. med. Forum* 2005;4:20-22.

Buchkapitel

Imhof A. Miscellaneous antibacterial drugs, chapter 26. Side effect of drugs, annual 28. Aronson J (ed.). Elsevier 2005:274-293.

Weber R, A. F. Status febrilis. In: W. Siegenthaler (ed.) *Differentialdiagnose innerer Krankheiten*. Georg Thieme Verlag, Stuttgart 2005:108-205.

Buchkapitel in print (2006)

Imhof A. Miscellaneous antibacterial drugs, chapter 26. Side effect of drugs, annual 29. Aronson J (ed.). Elsevier 2006;in print.

Zinkernagel AS, von Overbeck J. HIV and AIDS, Chapter 36, Medical Selection of Life Risks. 5th Edition of Brackenridge's Medical Selection of Life Risks (MacMillan publisher). 2006; in print.

Weber R, Mathis A, Deplazes P. Microsporidia. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Tenover FC, Tenover FC (eds). Manual of Clinical Microbiology. American Society for Microbiology, 9th Edition, ASM Press Washington D.C. 2006;in print.

Andere Arbeiten

Jeker K, Weber R, Schulthess G, Furrer J. Multilokuläre grosse Erytheme und Fieber. Schweiz Rundsch Med Prax 2005;94(46):1815-9.

Schröder-Frei B, Zinkernagel AS, Thiel MA. Antibiotikatherapie am Auge: Teil 2, ein praktisches Behandlungskonzept, 2005.

Thiel MA, Yanar A, Zinkernagel AS. Antibiotikatherapie am Auge: Teil 1, Grundlagen für den Praktiker, 2005.